BCX-CM-Sec
BCX-CM-Sec
A research project aimed at developing a cell-free biological drug effective in combating atopic dermatitis in dogs. The active substance of the drug consists of the entirety of factors secreted by stem cells. These include numerous cytokines and chemokines, growth factors, peptides, and nucleic acids. Properly prepared secretome contains a variety of molecules with immunomodulatory and anti-inflammatory activity. A secretome-based drug has the potential to be as effective as cell-based products, while at the same time being more convenient to use and significantly more accessible to patients.
Disease
Canine atopic dermatitis (CAD) is a skin disorder with a complex etiology. The most commonly cited contributing factors include genetic predisposition, an increased tendency toward allergic reactions, exposure to chemical agents, environmental pollutants, and disturbances in the normal skin microbiota. CAD is a progressive, chronic, and relapsing condition, and by the time overt clinical signs become apparent—such as erythema, pruritus, visible skin lesions, exudation, localized infections, and pain of varying severity—the disease is often already at an advanced stage and difficult to manage therapeutically. Treatment of CAD is therefore typically focused primarily on alleviating clinical symptoms rather than addressing the underlying causes. It is estimated that approximately 15% of the canine population is affected by atopic dermatitis.
Existing treatment
Currently available therapies do not resolve the underlying problem of atopy, as they rely primarily on the elimination of sensitizing allergens, which is often extremely challenging. Consequently, treatment is largely symptomatic and typically involves the administration of antihistamines, corticosteroids, and immunosuppressive agents. These therapies may lead to excessive suppression of the immune system, frequently resulting in secondary infections, such as fungal diseases. Moreover, anti-inflammatory treatments do not provide long-term benefits, and their prolonged use is associated with an increased risk of adverse side effects.
Others
BCX-CM-J
BCX-CM-AD
